Upon the Effective Time, the Company became a wholly owned subsidiary of Parent. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Pursuant to the Merger Agreement, as of the Effective Time, the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. The directors of Purchaser at the Effective Time were Vincent M. Servello, James H. Thomasson and John A. Sperino.
Departed
Arlen R. Shenkman
Director
Aspen Technology, Inc.
Effective
2025-03-12
Filed
March 12, 2025, 7:59 PM ET
As of the Effective Time, Antonio J. Pietri, Robert M. Whelan, Jr., Patrick M. Antkowiak, Thomas F. Bogan, Karen M. Golz, David J. Henshall, Ram R. Krishnan and Arlen R. Shenkman each ceased to be directors of the Company
Appointed
James H. Thomasson
Director
Aspen Technology, Inc.
Effective
2025-03-12
Filed
March 12, 2025, 7:59 PM ET
Upon the Effective Time, the Company became a wholly owned subsidiary of Parent. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Pursuant to the Merger Agreement, as of the Effective Time, the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. The directors of Purchaser at the Effective Time were Vincent M. Servello, James H. Thomasson and John A. Sperino.
Departed
David J. Henshall
Director
Aspen Technology, Inc.
Effective
2025-03-12
Filed
March 12, 2025, 7:59 PM ET
As of the Effective Time, Antonio J. Pietri, Robert M. Whelan, Jr., Patrick M. Antkowiak, Thomas F. Bogan, Karen M. Golz, David J. Henshall, Ram R. Krishnan and Arlen R. Shenkman each ceased to be directors of the Company
Departed
Patrick M. Antkowiak
Director
Aspen Technology, Inc.
Effective
2025-03-12
Filed
March 12, 2025, 7:59 PM ET
As of the Effective Time, Antonio J. Pietri, Robert M. Whelan, Jr., Patrick M. Antkowiak, Thomas F. Bogan, Karen M. Golz, David J. Henshall, Ram R. Krishnan and Arlen R. Shenkman each ceased to be directors of the Company
Appointed
John A. Sperino
Director
Aspen Technology, Inc.
Effective
2025-03-12
Filed
March 12, 2025, 7:59 PM ET
Upon the Effective Time, the Company became a wholly owned subsidiary of Parent. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Pursuant to the Merger Agreement, as of the Effective Time, the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. The directors of Purchaser at the Effective Time were Vincent M. Servello, James H. Thomasson and John A. Sperino.
On March 11, 2025, the Board of Directors (the “Board”) of Cherry Hill Mortgage Investment Corporation (the “Company”) increased the size of the Board from four directors to five directors and appointed Dale S. Hoffman as a director.
Appointed
Sylvie Ouziel
Director
WNS (HOLDINGS) LTD
Effective
2025-04-01
Filed
March 12, 2025, 7:59 PM ET
WNS (Holdings) Limited appointed Sylvie Ouziel to the Company’s Board of Directors effective April 1, 2025.
Appointed
Neal P. Goldman
Director
IROBOT CORP
Effective
2025-03-10
Filed
March 12, 2025, 7:59 PM ET
the Board expanded the size of the Board from eight to nine members and appointed Neal P. Goldman to the Board as a Class II director to fill the newly created vacancy.
On March 6, 2025, Ng Keok Chai resigned from his position as Independent Director and Head of the Audit Committee of Graphjet Technology (the “Company”).
On March 10, 2025, Tina Hunt informed the board of directors (the “Board”) of Veeva Systems Inc. (“Veeva”) of her intention to retire from her role as a director on the Board, effective immediately prior to the 2025 annual meeting of Veeva’s shareholders (the “2025 Annual Meeting”).
On March 7, 2025, the Board of Directors of the Company (the “Board”) appointed Peter Laurinaitis to serve as a Class III independent director effective immediately following the filing of the Company’s Annual Report on Form 10-K
On March 10, 2025, the Board of Directors (the “Board”) of NPK International Inc. (“the Company”) elected to increase the size of the Board from seven directors to eight directors effective March 10, 2025 and appointed Mr. Joseph A. Cutillo to fill the resulting vacancy.
Appointed
Mark Ward
Director
ContextLogic Inc.
Effective
2025-03-06
Filed
March 11, 2025, 7:59 PM ET
On March 6, 2025, the Board appointed Ted Goldthorpe and Mark Ward as directors of the Board (collectively, the “New Directors”), with Mr. Goldthorpe serving as Chairman.
On March 10, 2025, the Board of Directors (the “Board”) of Smurfit Westrock plc (the “Company”) appointed Carole L. Brown to the Board as an independent director, effective March 11, 2025.
As previously disclosed, Dmitri L. Stockton will be stepping down from the Board, effective as of the conclusion of the Company’s 2025 Annual General Meeting of Shareholders
the Board of Directors of Vitesse (the “Board”) approved an increase in the size of the Board from seven to nine directors and appointed M. Bruce Chernoff and Gary D. Reaves.
the Board of Directors of Vitesse (the “Board”) approved an increase in the size of the Board from seven to nine directors and appointed M. Bruce Chernoff and Gary D. Reaves.
On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.
On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.
On March 11, 2025, Las Vegas Sands Corp.’s (the “Company’s”) Board of Directors (the “Board”) elected Muktesh “Micky” Pant as a new member of the Board, effective immediately.
On March 6, 2025, the Board of Directors (the “Board”) of ICF International, Inc. (the “Company”) increased the size of the Company’s Board from seven (7) to eight (8) members and announced the appointment of Ms. Caroline Angoorly to the Board.
On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.
On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.
Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.
On March 6, 2025 and March 7, 2025, Ryan Wright and David Jolley were elected as directors of Domo, Inc. (the "Company"), effective March 6, 2025 and March 7, 2025, respectively
On March 6, 2025 and March 7, 2025, Ryan Wright and David Jolley were elected as directors of Domo, Inc. (the "Company"), effective March 6, 2025 and March 7, 2025, respectively
On March 5, 2025, Dr. Stefan Piëch, a member of the Board of Directors (the “Board”) of Kartoon Studios, Inc. (the “Company”), notified the Company of his decision to resign, effective as such date, from his position as a member of the Board.
On March 11, 2025, Sandra J. DiCocco was appointed as Chairman of the Board of Directors of the Company, and Vincent Monteparte, Ross David Gourdie and Amy Scannell were appointed members of the Board of Directors.
On March 11, 2025, Sandra J. DiCocco was appointed as Chairman of the Board of Directors of the Company, and Vincent Monteparte, Ross David Gourdie and Amy Scannell were appointed members of the Board of Directors.
Appointed
Anthony Merchant
Director
Tofla Megaline Inc.
Effective
2025-03-07
Filed
March 11, 2025, 7:59 PM ET
Further, on March 7, 2025, Anthony Merchant and Alejandro Araujo were appointed as members of the Board of Directors of the Company.
Appointed
Alejandro Araujo
Director
Tofla Megaline Inc.
Effective
2025-03-07
Filed
March 11, 2025, 7:59 PM ET
Further, on March 7, 2025, Anthony Merchant and Alejandro Araujo were appointed as members of the Board of Directors of the Company.
On March 7, 2025, Anne G. Waleski advised Enact Holdings, Inc. (the “Company”) and the Company’s Board of Directors (the “Board”) of her intention not to stand for re-election as a director of the Company when her term expires at the Company’s upcoming 2025 Annual Meeting of Stockholders on May 14, 2025.
On March 11, 2025, the Board of Directors (the “Board”) of Enact Holdings, Inc., a Delaware Corporation (the “Corporation” or “Enact”), appointed H. Elizabeth Mitchell to serve as a director for a term expiring at the 2025 Annual Meeting of Stockholders.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On March 7, 2025, the Board (i) increased the size of the Board from eight to nine members by adding a Class I directorship and (ii) appointed Eric V. Roegner as a Class I director, effective immediately, to fill the Class I directorship vacancy resulting from the increase of the size of the Board with his initial term expiring at the 2025 annual meeting of stockholders of the Company ("2025 Annual Meeting").
Appointed
Yehia Hashad
Director
Unity Biotechnology, Inc.
Effective
2025-03-08
Filed
March 10, 2025, 7:59 PM ET
On March 8, 2025, the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) appointed Dr. Yehia Hashad, M.D., current executive vice president of research & development and chief medical officer at Bausch + Lomb, to the Board and as a member of the Science Committee, effective immediately.
On March 9, 2025, Guillaume Pepy notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision not to seek re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders, when his current term expires.
On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.
On March 7, 2025, Mr. Brian N. Hansen, a member of our Board of Directors (the “Board”), notified us of his decision not to stand for re-election at our upcoming 2025 annual meeting of stockholders scheduled for May 15, 2025 (the “2025 Annual Meeting”).
On March 6, 2025 (the “Effective Date”), Mark J. Frohlich was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.